Skip to main content
Log in

Valproic Acid Aggravates Epilepsy due to MELAS in a Patient with an A3243G Mutation of Mitochondrial DNA

  • Original Paper
  • Published:
Metabolic Brain Disease Aims and scope Submit manuscript

An Erratum to this article was published on 05 September 2007

An Erratum to this article was published on 05 September 2007

Abstract

Epilepsy is one of the most common presentations of patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). MELAS is typically caused by an A-to-G substitution at nucleotide position 3243 of mitochondrial DNA. Valproic acid, a common anticonvulsant, can actually increase the frequency of seizures in individuals with MELAS. Here, we report a single case-study of a 38-year-old man who presented with focal seizures and had MELAS Syndrome due to the A3243G mitochondrial DNA mutation. Manifestation of epilepsia partialis continua was aggravated by use of valproic acid. Convulsions abated after discontinuation of valproic acid. Our experience suggests that valproic acid should be avoided for the treatment of epilepsy in individuals with mitochondrial disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Altrup U, Gerlach G, Reith H, Said MN, Speckmann EJ (1992) Effects of valproate in model nervous system (buccal ganglia of Helix pomatia): I. Antiepileptic actions. Epilepsia 33:743–752

    Article  PubMed  CAS  Google Scholar 

  • Altrup U, Reith H, Speckmann EJ (1992) Effects of valproate in a model nervous system (buccal ganglia of Helix pomatia): II. Epileptogenic actions. Epilepsia 33:753–759

    Article  PubMed  CAS  Google Scholar 

  • Aure K, Jardel C, Lombes A (2005) Mitochondrial diseases: Molecular mechanisms, clinical presentations and diagnosis investigations. Ann Pathol 25:270–281

    PubMed  Google Scholar 

  • Chabrol B, Mancini J, Chretien D, Rustin P, Munnich A, Pinsard N (1994) Valproate-induced hepatic failure in a case of cytochrome c oxidase deficiency. Eur J Pediatr 153:133–135

    PubMed  CAS  Google Scholar 

  • Chinnery PF, Howell N, Lightowlers RN, Tumball DM (1997) Molecular pathology of MELAS and MERRF: The relationship between mutation load and clinical phenotypes. Brain 120:1713–1721

    Article  PubMed  Google Scholar 

  • Dimauro S, Davidzon G (2005) Mitochondrial DNA and disease. Ann Med 37:222–232

    Article  PubMed  CAS  Google Scholar 

  • Krahenbuhl S, Brandner S, Kleinle S, Liechti S, Straumann D (2000) Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver 20:346–348

    Article  PubMed  CAS  Google Scholar 

  • Kunz WS (2002) The role of mitochondria in epileptogenesis. Curr Opin Neurol 15:179–184

    Article  PubMed  Google Scholar 

  • Lam CW, Lau CH, Williams JC, Chan YW, Wong LJ (1997) Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr 156:562–564

    Article  PubMed  CAS  Google Scholar 

  • Liou CW, Huang CC, Chee EC, Jong YJ, Tsai JL, Pang CY, Lee HC, Wei YH (1994) MELAS Syndrome: Correlation between clinical features and molecular genetic analysis. Acta Neurol Scand 90:354–359

    Article  PubMed  CAS  Google Scholar 

  • Morris AA (1999) Mitochondrial respiratory chain disorders and the liver. Liver 19:357–368

    Article  PubMed  CAS  Google Scholar 

  • Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP (1984) Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes: A distinctive clinical syndrome. Ann Neurol 16:481–488

    Article  PubMed  CAS  Google Scholar 

  • Ponchaut S, Van Hoof F, Veitch K (1992) Cytochrome aa3 depletion is the cause of the deficient mitochondrial respiration induced by chronic valproate administration. Biochem Pharmacol 43:644–647

    Article  PubMed  CAS  Google Scholar 

  • Ponchaut S, Van Hoof F, Veitch K (1995) Valproate and cytochrome c oxidase deficiency. Eur J Pediatr 154:79

    Article  PubMed  CAS  Google Scholar 

  • Scaglia F, Northrop JP (2006) The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: A review of treatment options. CNS Drugs 20:443–464

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Chih-Ming Lin.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s11011-007-9056-3

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lin, CM., Thajeb, P. Valproic Acid Aggravates Epilepsy due to MELAS in a Patient with an A3243G Mutation of Mitochondrial DNA. Metab Brain Dis 22, 105–109 (2007). https://doi.org/10.1007/s11011-006-9039-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11011-006-9039-9

Keywords

Navigation